Usefulness of Circulating CYFRA21-1 in Patients as a Biomarker in Patients Taking Sorafenib or Lenvatinib for Unresectable Hepatocellular Carcinoma

Background: This study investigated the impact of serum cytokeratin 19 fragment (CYFRA21-1) level on the clinical outcomes of patients with unresectable hepatocellular carcinoma (HCC) treated with sorafenib (SOR) or lenvatinib (LEN). Methods: A total of 71 cases with unresectable HCC taking SOR or L...

詳細記述

書誌詳細

主要な著者:	Hitomi Takada, Leona Osawa, Yasuyuki Komiyama, Ryoh Kato, Natsuko Nakakuki, Masaru Muraoka, Yuichiro Suzuki, Akihisa Tatsumi, Mitsuaki Sato, Ei Takahashi, Shinichi Takano, Mitsuharu Fukasawa, Tatsuya Yamaguchi, Taisuke Inoue, Shinya Maekawa, Nobuyuki Enomoto
フォーマット:	Artigo
言語:	Inglês
出版事項:	MDPI AG 2021-08-01
シリーズ:	Reports
主題:	CYFRA21-1 hepatocellular carcinoma sorafenib lenvatinib
オンライン･アクセス:	https://www.mdpi.com/2571-841X/4/3/25
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!